Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (1210)	9/19/2002 9:49:54 AM
From: tuck	Read Replies (1) \| Respond to of 1784

IonWorks: MDCC has been yapping about that for a while now; let's see how it sells. Meanwhile MDS (MDZ) is the trickle earnings bellwether because they report first. Their report is so long I'm just going to link it from their home page and hope the link doesn't expire: corporate-ir.net Believe it or not, that's from their home page. Anyhow, it looks like a solid quarter at first blush. Cheers, Tuck

To: mopgcw who wrote (1210)	11/20/2003 12:57:25 PM
From: tuck	Read Replies (2) \| Respond to of 1784

MDCC is the current gorilla in the ion channel/patch clamp space, but Sweden's Cellectricon threatens. MDCC might consider munching them. the-scientist.com This article seems to ignore the throughput the IonWorks HT system is capable of -- also thousands of patches per day (see referenced post) -- nevertheless, with several big pharmas already Cellectricon customers, it's very much a horse race in this market. If memory serves (can't find my notes) MDCC has called this a $500 million market opportunity. Cheers, Tuck